View Alert


Originator: CMO Messaging

From: CMO Messaging

Issue date: 04-Nov-2021 10:47:07

This alert has been issued to:
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • Consultants in Communicable Diseases
  • NHS Trusts (England) - Chief Executive

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health

Action category: Action

Title: Casirivimab and imdevimab in the treatment of COVID-19 in hospitalised patients

Broadcast content:
NHS access to the combination monoclonal antibody casirivimab plus imdevimab (marketed as Ronapreve┬«) has been extended in patients aged 12 and above and should now be considered at a total dose of 2.4g in COVID positive antibody seronegative patients who have been hospitalised specifically to manage the symptoms of COVID infection; and at a total dose of 1.2g in patients who are admitted to hospital for another (non COVID-related) indication but nonetheless test positive during their hospital stay and are either at high risk of disease progression or COVID infection is considered to be likely to destabilise their existing medical condition or compromise recovery from their hospital procedure. 

The extension of access to patients with hospital-onset infection will enable a further evaluation of clinical adoption in this cohort.


Additional information: NHS Trusts and Foundation Trusts are asked to ensure this alert is shared with Pathology Directors / networks.

This alert is not relevant to primary care.


Alert reference: CEM/CMO/2021/018

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency